Full Press Release Details
1 Disclaimer This presentation, the information contained herein and the
materials accompanying it (together, this "presentation") contains confidential, material and non-public information regarding Allurion Technologies, Inc. (the "Company" or "us") and is provided to the recipients
("you") of this presentation on the condition that you agree to hold it in strict confidence and not reproduce, disclose, forward or distribute it in whole or in part to others at any time without the prior written consent of the
Company. By accepting this presentation, you expressly agree to maintain the confidentiality of the material and information contained or accompanying it and to use this presentation in accordance with your contractual obligations to the Company and
applicable law, including federal and state securities laws. This presentation contains forward-looking statements within the meaning of the federal securities laws, which are statements that involve substantial risks and uncertainties.
Forward-looking statements generally relate to future events or the Company's future financial or operating performance. All statements other than statements of historical fact included in this presentation, including statements regarding the
Company's strategy, future operations, financial position, estimated revenue and losses, projected costs, volume of procedures, prospects, plans, and objectives of management are forward-looking statements. In some cases, you can identify
forward-looking statements because they contain words such as "may," "will," "shall," "should," "expects," "plans," "anticipates," "could,"
"intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," or "continue" or the negative of these
words or other similar terms or expressions that concern the Company's expectations, strategy, plans or intentions. The Company has based the forward-looking statements contained in this presentation primarily on management's current
beliefs and the Company's current expectations and projections about future events and trends that it believes may affect its business, results of operations, financial condition, and prospects. Moreover, the Company operates in a very
competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for the Company to predict all risks and uncertainties that could have an impact on the forward-looking statements contained
in this presentation. The results, events, and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events, or circumstances could differ materially from those described in the forward-looking
statements. There are a number of factors, many of which are beyond the Company's control, that could cause actual results to differ materially from the results anticipated by these forward-looking statements, including, among others: the
Company's expectations regarding its revenue, expenses, and other operating results; the Company's ability to acquire new customers or distributors and grow its customer base; the Company's ability to successfully retain existing
customers and distributors and expand sales within its existing customer base; the Company's ability to launch its existing products in new markets or launch new product developments and offerings, including the Company's digital health
platform and artificial intelligence tools; regulatory approvals for the Company's products, including approval of the Company's gastric balloon in the U.S. and any expanded label uses; future investments in developing and enhancing the
Company's business; the Company's expectations regarding its ability to expand; the Company's anticipated capital expenditures and its estimates regarding the Company's capital requirements; investments in the Company's
selling and marketing efforts; the Company's ability to compete effectively with existing competitors and new market entrants; the total addressable markets for the Company's products; the Company's reliance on its senior
management team and its ability to identify, recruit, and retain skilled personnel; the Company's ability to effectively manage its growth; economic and industry trends and other macroeconomic factors, such as fluctuating interest rates,
rising inflation and consumer sentiment; and the impact of global pandemics, health crises, political conflicts and other global financial, economic, and political events on the Company's industry, business, and results of operations. Should
one or more of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, the Company's actual results may vary in material respects from those projected in these forward-looking statements.
Factors or events that could cause the Company's actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The forward-looking statements made in this presentation relate only to
events as of the date on which the statements are made. The Company undertakes no obligation to update any forward-looking statements made in this presentation to reflect events or circumstances after the date of this presentation or to reflect new
information or the occurrence of unanticipated events, except as required by applicable law. The Company may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue
reliance on the Company's forward- looking statements. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the
forward-looking statements, see the section entitled "Risk Factors" in our most annual report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), as well as discussions of potential risks,
uncertainties and other important factors in our other subsequent filings with the SEC. This presentation contains financial forecasts with respect to the Company's projected financial results for the Company for the periods indicated. These
projections should not be relied upon as being necessarily indicative of future results. The assumptions and estimates underlying the prospective financial information are inherently uncertain and are subject to a wide variety of significant
business, economic and competitive risks and uncertainties that could cause actual results to differ materially from those contained in the prospective financial information. Actual results may differ materially from the results contemplated by the
projected financial information contained in Confidential Information this presentation and the inclusion of such information should not be regarded as a representation by any person that the results reflected in such information will be achieved.
There can be no assurance that the prospective results are indicative of the future performance of the Company or that actual results will not differ materially from those presented in the prospective financial information. 2024 ALLURION
TECHNOLOGIES - PROPRIETARY INFORMATION
2 Disclaimer (Continued) This presentation is made pursuant to Section
5(d) and/or Rule 163B of the Securities Act of 1933, as amended (the "Securities Act"), and is intended solely for investors that are "qualified institutional buyers" as defined in Rule 144A under the Securities Act, or
institutions that are "accredited investors" as defined in Rule 501 of Regulation D under the Securities Act, solely for the purposes of familiarizing such investors with the Company and determining whether such investors might have an
interest in a securities offering contemplated by the Company. Any such offering of securities will only be made by means of a registration statement (including a prospectus) filed with the U.S. Securities and Exchange Commission, after such
registration statement becomes effective. No such registration statement has been publicly filed, or become effective, as of the date of this presentation. This presentation shall not constitute an offer to sell or the solicitation of an offer to
buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or
jurisdiction. This presentation does not purport to contain all of the information that may be required to evaluate any investment in the Company or any of its securities and should not be relied upon to form the basis of, or be relied on in
connection with, any contract or commitment or investment decision whatsoever. This presentation is intended to present background information on the Company, its business and the industry in which it operates and is not intended to provide complete
disclosure upon which an investment decision could be made. The merit and suitability of an investment in the Company should be independently evaluated and any person considering such an investment in the Company is advised to obtain independent
advice as to the legal, tax, accounting, financial and other related advice prior to making an investment. Any decision to purchase securities in any offering the Company may make in the future should be made solely on the basis of information
contained in any prospectus that may be prepared by the Company in final form in relation to any such proposed offering and which would supersede this presentation and information contained herein in its entirety. None of the Company or any of its
affiliates, directors, officers, employees, advisers, representatives or any other person makes any representation or warranty, expressed or implied, as to the accuracy or completeness of this presentation or any of the information contained herein,
or any other written or oral communication transmitted or made available to you or your affiliates or representatives. Accordingly, none of the Company or any of its affiliates, directors, officers, employees, advisers, representatives or any other
person shall be liable for any direct, indirect or consequential loss or damages suffered by any person based, in whole or in part, on the presentation or any information contained herein or any other written or oral communication transmitted or
made available to you or your affiliates or representatives, including, without limitation, with respect to errors therein or omissions therefrom, and any such liability is expressly disclaimed to the fullest extent permitted by law. made available
to Unless otherwise indicated, information contained in this presentation concerning the Company's industry, competitive position and the markets in which it operates is based on information from independent industry and research
organizations, other third-party sources, and management estimates. Management estimates are derived from publicly available information released by independent industry analysts and other third party sources, as well as data from the
Company's internal research, and are based on assumptions made by the Company upon reviewing such data, and the Company's experience in, and knowledge of, such industry and markets, which the Company believes to be reasonable. While the
Company believes that such third party information is reliable, the Company has not independently verified, and makes no representation as to the accuracy or completeness of, such third party information. All trademarks, service marks, and trade
names appearing in this presentation are the property of their respective holders and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of the Company. 2024 ALLURION
TECHNOLOGIES - PROPRIETARY INFORMATION
3 Transaction Summary Issuer Allurion Technologies, Inc. Ticker
(Listing) ALUR (NYSE) (1) Offering Amount $20.0 million (100% primary); includes common stock and warrants Warrants will be immediately exercisable at an exercise price equal to the offer price and will expire five years from the Warrants date of
issuance; 100% warrant coverage To fund clinical trials, commercial sales, research and development, and for working capital and other general corporate Use of Proceeds purposes Lock-Up Period 90 days for Company, Directors & Officers
Book-Runners Jefferies, TD Cowen Co-Manager Roth Capital Partners th Expected Pricing June 27 , 2024 (post-market close) 1) RTW Investments, LP ("RTW"), a significant stockholder, has indicated an interest in investing an aggregate of
$3.0 million in this offering and in a concurrent private placement of a newly-created series of preferred stock, Series A convertible preferred stock (the "Series A preferred stock") and accompanying private placement warrants.
2024 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION
4 Investment Highlights Allurion is well-positioned for growth in 2024
and beyond 1 Large addressable market that is continuing to grow; $54B obesity treatment market expected by 2030 Innovative gastric balloon technology that drives durable total body weight loss (14% with one balloon and 23% with two 2 balloons),
with excellent safety profile 3 Strong international business with $53M in revenue and 78% GM in 2023, with path to profitability 4 Robust procedure volume growth; targeting ~20% YoY growth in 2024 5 FDA AUDACITY trial data expected by year-end 2024
enabling entry into $18B U.S. opportunity, if approved by the FDA 6 Commercializing AI-powered digital platform globally, including in the U.S. market; leveraging tailwinds from GLP-1s 2024 ALLURION TECHNOLOGIES - PROPRIETARY
5 Obesity Is A Significant Problem With Society-Wide Health And Economic
Ramifications Massive market opportunity with $54B revenue opportunity by 2030 The Problem The Opportunity 60 50 40 30 20 10 0 2024 2025 2026 2027 2028 2029 2030 US revenues Ex-US revenues $54B obesity treatment market expected by 2030 Growth driven
primarily by GLP-1 drug adoption and fueled 4 by growing interest in weight management solutions 1) World Obesity Federation, "Global Obesity Observatory". 2) Telem, D., Greenstein A., Wolfe B. (2024), Outcomes of bariatric surgery,
UpToDate. 3) Murtha et. al. Individual-level barriers to bariatric surgery from patient and provider perspectives: A qualitative study. doi: 10.1016/j.amjsurg.2021.12.022. 4) Morgan Stanley, "Unlocking the Obesity Challenge". 2024
ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION $ Billion
6 Other Weight-Loss Therapies Bariatric surgical procedures and other
existing balloons have notable shortcomings Flawed Poor High Poor Go-To-Market Experience Risks Economics Limited Channels Execution Lack of post- Invasive All-in costs for Existing approach Previous procedure patient procedures are cash-pay
bariatric lacks scalable companies failed monitoring and inherently risky in surgery is infrastructure and to embrace behavior a high BMI ~$14,000 on training to deliver modern-day modification population, average and up to comprehensive digital
advertising programs especially where ~$33,000, with weight loss and account patients undergo limited insurance programs training to 1 2 anesthesia coverage drive growth 1) ASA. 2) Doble et al. Obes Surg. 2017; 27(8): 2179-2192. 2024 ALLURION
TECHNOLOGIES - PROPRIETARY INFORMATION
We believe the Allurion balloon solves shortcomings of other treatments
The world's first and only Procedureless weight loss device A breakthrough in simplicity 1* Procedureless - swallowed in 15-minute office visit without surgery, endoscopy, or anesthesia Unintrusive - ~4 months after
placement, a time-activated release valve constructed from a 1 proprietary polymer opens, allowing the balloon to pass naturally through the GI tract Innovative - Covered by over 50 patents and made from biocompatible polyurethane designed 1*
to be gentle on the stomach lining Significantly improved patient experience 2- 8 Lower serious adverse event rate - 10x lower than other liquid-filled balloons Lower intolerance requiring balloon removal - ~1-3% intolerance rate
vs. 14-17% for 12-month 9-10 endoscopic balloons Increasing global availability First Allurion Balloons available on NHS in UK - in discussions with healthcare trusts to roll out more broadly FDA AUDACITY trial readout expected by year
end 2024 1) Taha et al. Obesity Surgery. 2020. 5) Moore et al., 2020. 9) Jamal MH et al. Obesity Surgery, 2021. 2) Ponce et al. Surg Obes Relat Dis. 2015. 6) Abu Dayyeah et al., 2021. 10) Abu Dayyeh BK et al. Lancet, 2021. 3) US FDA Post-Approval
Studies Database Application #P140012. 7) Allurion Enlighten Trial. 4) Orbera Pivotal Trial NCT00730327. 8) Ienca et al. 2020. Note: *The Allurion Balloon is an investigational device in the United States and has not been cleared or approved by the
U.S. Food and Drug Administration (FDA). In rare cases, endoscopic or surgical intervention 2024 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION may be required for removal.
8 The Allurion Balloon Is Paired With The Virtual Care Suite Allurion
Allurion Patient App Connected Scale 3 Tracks weight and Analyzes data, body composition, provides real-time empowering and insights, enables enabling patients to sharing with care reach their goals Allurion team, and syncs with the user's own
Insights smartwatch to track activity and sleep Coach Iris Patient and clinic-level data for improved patient care and clinic management AI-powered virtual weight loss coach that supports patients 24/7 2024 ALLURION TECHNOLOGIES - PROPRIETARY
9 Comprehensive Clinical Data Supports The Allurion Balloon's
Efficacy Profile Allurion Balloon Led to 96% of Weight Loss Sequential Allurion Treatment 1 2 3 15% Weight Loss in Just 4 Months Maintained After 1 Year Led to 23% Weight Loss After two sequential balloons, % TBWL 30% was Weight Loss achieved
in 26% of patients (% TBWL) 15% Weight (kg) % TBWL 13% 23% 96% weight 22 maintenance 13.9% on average 13.4% 10% 15 14% 7% 6% 5% 5% 3% 0% 0% %TBWL Weight Loss (kg) Weight Loss % 1 Balloon 2 Balloons 4 Months 1 Year Allurion Lifestyle Intervention 1)
Raftopoulos Y, et al. Poster at the 37th ASMBS Annual Meeting, 2021. 2) Ienca R, et al. Long-Term Efficacy of the Elipse Gastric Balloon System: An International Multicenter Study, 2020. 3) Ienca R, et al. Sequential Elipse Balloon Treatment 1 Year
Weight Loss Results Approximate Bariatric Surgery Results, 2020. 2024 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION
10 The Allurion Balloon Can Also Impact Co-morbidities, Including
Diabetes 1 Positive Early Clinical Results In Diabetic / Pre-diabetic Patients The Allurion Balloon Can Impact Co-morbidities In a study of 518 patients (225 w. diabetes / 293 w. pre-diabetes), majority In 115 patients treated with the Allurion
program with of patients entered remission four months after balloon insertion co-morbidities, resolution rates were greater than 50% 2 Percentage of Patients With Resolution of Co-Morbidity HbA1c (%) 23% on average 59% 14% on average 58% 7.1% 5.9%
5.5% 5.1% 56% Diabetes Pre-diabetes Type 2 diabetes Hypertension Obstructive sleep apnea A1c before balloon placement A1c after balloon placement 1) Ienca R, et al. Oral presentation at IFSO; Napoli, Italy, 2023. 2) Mathur W, et al. "Effect of
swallow balloon therapy with the combination of semaglutide oral formulation: A randomised double-blind single-centre study." Obesity Surgery, 2023. 3) Ienca R, Oyola C, Giardiello C, et al. The Swallowable Gastric Balloon: Global Experience
in 5003 Consecutive Patients - The Largest Gastric Balloon Study in the World. Oral presentation at IFSO; Napoli, Italy, 2023. 2024 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION
11 The Allurion Balloon Was Designed To Be Safer Than Alternatives
Allurion Results Demonstrate Tolerance Compared to Other Balloons, The Allurion Balloon Thanks To A Unique Design Results In Fewer Serious Adverse Events (SAEs) Device- or procedure-related SAE rates 10.0% Conforms to the shape of the 01 stomach
- an oval shape like a 7.5% grapefruit, with two flat surfaces 5.3% N=1,770 0.4% Made from polyurethane - thinner 02 and more flexible than the silicone Spatz ReShape Orbera Allurion (Ienca et al.) in endoscopic balloons SAE rate over
10X lower than other liquid- filled balloons* Designed to be gentle on the 03 stomach lining and reduce GI adverse events and intolerance Intolerance rates for endoscopic balloons are 4, 5 7-8X higher than the Allurion Balloon 1) Spatz SSED (Nov